- The magazine
- Cancer Biology
- Chromatography & Mass Spectrometry
- Contract Research
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & Rapid Micro Methods (RMMs)
- Process Analytical Technology (PAT) & Quality by Design (QbD)
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Cell based assays for screening workshop – May 2014
- Biochemical assays for screening workshop – July 2014
- Cell based assays for screening workshop – November 2014
- 3D cell based assays: Advanced workshop – November 2013
- Chemical Biology, Drug Discovery & Screening workshop – October 2013
- Cell based assays for screening workshop – June 2013
- Biochemical Assays Workshop – April 2013
- Biochemical Assays Workshop 2012
- Pharma industry events
- About us
- Contact us
Publication date: 3 December 2012
Author(s): Novo Nordisk
Ryzodeg® passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan
Novo Nordisk today announced that Ryzodeg® (insulin degludec/insulin aspart) has passed the review by the First Committee on Drugs of Japan’s Pharmaceutical Affairs. The remaining step in the regulatory process is an approval from the Ministry of Health, Labour and Welfare.
The First Committee on Drugs of Pharmaceutical Affairs serves as an advisory body to the Ministry in matters related to pharmaceuticals including new drug applications. The passing of the review by the drug committee is an essential milestone in the Japanese review process prior to a marketing authorisation from the Ministry.
Novo Nordisk expects to receive marketing authorisation from the Ministry within a few months.
In Japan, price negotiations for Tresiba® (insulin degludec) continue and are expected to be completed in the first quarter of 2013. The exact launch timing for Ryzodeg® is to be decided after the Tresiba® price listing.
About Tresiba® and Ryzodeg®
Tresiba® is the intended brand name for insulin degludec, the first once-daily newgeneration basal insulin analogue, with an ultra-long duration of action, discovered and developed by Novo Nordisk. Tresiba® has a distinct slow absorption which provides a flat and stable action profile. Tresiba® has been studied in a large-scale clinical trial programme, BEGIN™, examining its impact on glucose control, hypoglycaemia and the possibility to flexibly adjust Tresiba® dosing time to suit patient needs.
Ryzodeg® is the intended brand name for insulin degludec/insulin aspart, which contains the new-generation basal insulin degludec in a formulation with a bolus boost of insulin aspart. Ryzodeg® is the first and only soluble insulin combination of ultra-long-acting insulin degludec and the most prescribed rapid-acting insulin, NovoRapid® (NovoLog® in the US), providing both fasting and post-prandial glucose control. Tresiba® and Ryzodeg® were submitted for regulatory approval to the Japanese Ministry of Health, Labour and Welfare (MHLW) in December 2011 and March 2012, respectively. Tresiba® was approved in Japan in September 2012 and in October 2012 Tresiba® and Ryzodeg® received positive CHMP opinions in Europe. In November, the products received a positive vote for approval from an FDA Advisory Committee. In addition, applications have been submitted for regulatory approval in Canada, Switzerland and a range of other countries.
ABB Analytical Measurement Analytik Jena AG Azbil BioVigilant, Inc. B&W Tek, Inc. bioMérieux BMG LABTECH GmbH Bruker Daltonik GmbH CAMO Software AS CI Precision Dow Chemical Company Ltd EUROGENTEC FOSS NIRSystems, Inc. GE Analytical Instruments IDBS IONICON Analytik GmbH LI-COR Biosciences Natoli Engineering Company, Inc. Pall Life Sciences PhyNexus, Inc. ReAgent Sirius Analytical Instruments Ltd Vala Sciences Veltek Associates Inc. Waters Corporation